Evolus (EOLS) Competitors $10.67 -0.17 (-1.57%) (As of 11:58 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends EOLS vs. TWST, ACAD, VCEL, MOR, SWTX, KYMR, ZLAB, GMTX, VERA, and BHCShould you be buying Evolus stock or one of its competitors? The main competitors of Evolus include Twist Bioscience (TWST), ACADIA Pharmaceuticals (ACAD), Vericel (VCEL), MorphoSys (MOR), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Zai Lab (ZLAB), Gemini Therapeutics (GMTX), Vera Therapeutics (VERA), and Bausch Health Companies (BHC). These companies are all part of the "pharmaceutical products" industry. Evolus vs. Twist Bioscience ACADIA Pharmaceuticals Vericel MorphoSys SpringWorks Therapeutics Kymera Therapeutics Zai Lab Gemini Therapeutics Vera Therapeutics Bausch Health Companies Twist Bioscience (NASDAQ:TWST) and Evolus (NASDAQ:EOLS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends. Is TWST or EOLS more profitable? Evolus has a net margin of -22.33% compared to Twist Bioscience's net margin of -66.69%. Twist Bioscience's return on equity of -32.27% beat Evolus' return on equity.Company Net Margins Return on Equity Return on Assets Twist Bioscience-66.69% -32.27% -25.37% Evolus -22.33%-847.60%-22.15% Do institutionals & insiders have more ownership in TWST or EOLS? 90.7% of Evolus shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by company insiders. Comparatively, 6.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk and volatility, TWST or EOLS? Twist Bioscience has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Does the MarketBeat Community believe in TWST or EOLS? Evolus received 251 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 72.58% of users gave Evolus an outperform vote while only 59.06% of users gave Twist Bioscience an outperform vote. CompanyUnderperformOutperformTwist BioscienceOutperform Votes10159.06% Underperform Votes7040.94% EvolusOutperform Votes35272.58% Underperform Votes13327.42% Which has stronger earnings & valuation, TWST or EOLS? Evolus has lower revenue, but higher earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTwist Bioscience$312.97M9.29-$208.73M-$3.60-13.61Evolus$248.33M2.72-$61.69M-$0.91-11.73 Does the media refer more to TWST or EOLS? In the previous week, Twist Bioscience had 4 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Twist Bioscience and 1 mentions for Evolus. Twist Bioscience's average media sentiment score of 0.62 beat Evolus' score of 0.00 indicating that Twist Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Twist Bioscience 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend TWST or EOLS? Twist Bioscience presently has a consensus target price of $51.90, suggesting a potential upside of 5.90%. Evolus has a consensus target price of $23.00, suggesting a potential upside of 115.56%. Given Evolus' stronger consensus rating and higher probable upside, analysts clearly believe Evolus is more favorable than Twist Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Twist Bioscience 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70Evolus 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEvolus beats Twist Bioscience on 11 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EOLS vs. The Competition Export to ExcelMetricEvolusPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$675.64M$6.70B$5.23B$9.25BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-11.7310.6387.6217.25Price / Sales2.72195.201,167.09120.47Price / CashN/A57.1643.2337.83Price / Book-29.645.144.824.92Net Income-$61.69M$151.58M$120.46M$225.43M7 Day Performance-9.04%-1.09%-0.57%0.74%1 Month Performance-15.32%-3.43%15.69%2.37%1 Year Performance7.13%8.66%29.92%16.58% Evolus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EOLSEvolus3.4507 of 5 stars$10.67-1.6%$23.00+115.6%+8.8%$675.64M$248.33M-11.73170TWSTTwist Bioscience2.6059 of 5 stars$48.86+2.9%$51.90+6.2%+30.9%$2.90B$312.97M-13.19990ACADACADIA Pharmaceuticals3.8781 of 5 stars$17.35+0.5%$25.60+47.6%-45.3%$2.89B$726.44M22.13510VCELVericel1.2956 of 5 stars$57.97+0.9%$59.71+3.0%+64.1%$2.86B$226.84M957.83300Analyst UpgradeMORMorphoSys0.1343 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics1.8325 of 5 stars$38.16-0.4%$69.50+82.1%+4.9%$2.84B$5.45M-9.87305KYMRKymera Therapeutics2.2845 of 5 stars$43.73+3.8%$53.88+23.2%+58.7%$2.83B$87.56M-18.00170Positive NewsZLABZai Lab1.9855 of 5 stars$26.06-1.0%$55.00+111.1%+4.9%$2.83B$355.75M-9.512,175GMTXGemini TherapeuticsN/A$64.89+1.0%N/A+11.0%$2.81BN/A-64.8930VERAVera Therapeutics3.6404 of 5 stars$44.38+0.7%$59.22+33.4%+166.9%$2.81BN/A-16.8840Positive NewsBHCBausch Health Companies2.8764 of 5 stars$7.69-1.5%$7.75+0.8%+0.4%$2.78B$8.76B-16.2720,270 Related Companies and Tools Related Companies Twist Bioscience Competitors ACADIA Pharmaceuticals Competitors Vericel Competitors MorphoSys Competitors SpringWorks Therapeutics Competitors Kymera Therapeutics Competitors Zai Lab Competitors Gemini Therapeutics Competitors Vera Therapeutics Competitors Bausch Health Companies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:EOLS) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
